Latest news with #EricKaras
Yahoo
27-05-2025
- Business
- Yahoo
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June. Details outlined below. William Blair 45th Annual Growth Stock ConferencePresentation: Tuesday, June 3, 2025Time: 11:20 a.m. CTLocation: ChicagoA live webcast of the presentation will be available here. 2025 Jefferies Global Healthcare ConferencePresentation: Wednesday, June 4, 2025Time: 5:30 p.m. ETLocation: New York CityA live webcast of the presentation will be available here. ARS Pharma company management will also participate in one-on-one meetings with investors at the Scotiabank Third Annual Healthcare Canadian Investor Day, Tuesday, June 17, 2025, in Toronto. To access the live and archived webcasts for the investor conferences, please visit the Events & Presentations page in the 'Investors & Media' section of the Company's website. A replay of each of the webcasts will be available for 30 days following the event. About ARS Pharmaceuticals, Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing (trade name EUR in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit Investor Contact:Justin Chakma, ARS Pharmajustinc@ Media Contact:Christy Curran, Sam Brown in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-02-2025
- Health
- Yahoo
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the Oppenheimer 35th Annual Healthcare Conference being held virtually. Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Wednesday, February 12, 2025, at 2:40 p.m. ET. Company management will also participate in one-on-one meetings with investors. A live webcast of the fireside chat will be available here, and in the Investors & Media section of the Company's website. A replay of the webcast will be archived on the Company's website for 90 days. About ARS Pharmaceuticals, Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing 2 mg (trade name EUR in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit ARS Investor Contacts:Justin ChakmaARS Pharmaceuticalsjustinc@ ARS Media Contact:Christy CurranSam Brown in to access your portfolio
